298 related articles for article (PubMed ID: 21210745)
21. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.
Fura A; Shu YZ; Zhu M; Hanson RL; Roongta V; Humphreys WG
J Med Chem; 2004 Aug; 47(18):4339-51. PubMed ID: 15317447
[No Abstract] [Full Text] [Related]
22. Strategies and chemical design approaches to reduce the potential for formation of reactive metabolic species.
Argikar UA; Mangold JB; Harriman SP
Curr Top Med Chem; 2011; 11(4):419-49. PubMed ID: 21320068
[TBL] [Abstract][Full Text] [Related]
23. Novel metabolic bioactivation mechanism for a series of anti-inflammatory agents (2,5-diaminothiophene derivatives) mediated by cytochrome p450 enzymes.
Hu Y; Yang S; Shilliday FB; Heyde BR; Mandrell KM; Robins RH; Xie J; Reding MT; Lai Y; Thompson DC
Drug Metab Dispos; 2010 Sep; 38(9):1522-31. PubMed ID: 20530221
[TBL] [Abstract][Full Text] [Related]
24. Drug bioactivation, covalent binding to target proteins and toxicity relevance.
Zhou S; Chan E; Duan W; Huang M; Chen YZ
Drug Metab Rev; 2005; 37(1):41-213. PubMed ID: 15747500
[TBL] [Abstract][Full Text] [Related]
25. The role of biotransformation and bioactivation in toxicity.
Dekant W
EXS; 2009; 99():57-86. PubMed ID: 19157058
[TBL] [Abstract][Full Text] [Related]
26. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
Kalgutkar AS; Didiuk MT
Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
[TBL] [Abstract][Full Text] [Related]
27. Idiosyncratic toxicity: a convergence of risk factors.
Ulrich RG
Annu Rev Med; 2007; 58():17-34. PubMed ID: 16958561
[TBL] [Abstract][Full Text] [Related]
28. Selection of new chemical entities with decreased potential for adverse drug reactions.
Park KB; Dalton-Brown E; Hirst C; Williams DP
Eur J Pharmacol; 2006 Nov; 549(1-3):1-8. PubMed ID: 16979156
[TBL] [Abstract][Full Text] [Related]
29. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
30. Strategies for dealing with reactive intermediates in drug discovery and development.
Nassar AE; Lopez-Anaya A
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
[TBL] [Abstract][Full Text] [Related]
31. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
Tang W; Lu AY
Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
[TBL] [Abstract][Full Text] [Related]
32. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.
Prakash C; Sharma R; Gleave M; Nedderman A
Curr Drug Metab; 2008 Nov; 9(9):952-64. PubMed ID: 18991592
[TBL] [Abstract][Full Text] [Related]
33. Toxicophores: investigations in drug safety.
Williams DP
Toxicology; 2006 Sep; 226(1):1-11. PubMed ID: 16860917
[TBL] [Abstract][Full Text] [Related]
34. Designing around Structural Alerts in Drug Discovery.
Kalgutkar AS
J Med Chem; 2020 Jun; 63(12):6276-6302. PubMed ID: 31497963
[TBL] [Abstract][Full Text] [Related]
35. Bioactivation potential of thiophene-containing drugs.
Gramec D; Peterlin Mašič L; Sollner Dolenc M
Chem Res Toxicol; 2014 Aug; 27(8):1344-58. PubMed ID: 25014778
[TBL] [Abstract][Full Text] [Related]
36. Should the incorporation of structural alerts be restricted in drug design? An analysis of structure-toxicity trends with aniline-based drugs.
Kalgutkar AS
Curr Med Chem; 2015; 22(4):438-64. PubMed ID: 25388012
[TBL] [Abstract][Full Text] [Related]
37. Novel advances in biotransformation and bioactivation research-2019 year in review
Khojasteh SC; Driscoll JP; Jackson KD; Miller GP; Mitra K; Rietjens IMCM; Zhang D
Drug Metab Rev; 2020 Aug; 52(3):333-365. PubMed ID: 32645275
[TBL] [Abstract][Full Text] [Related]
38. Peroxidase-mediated bioactivation of hydroxylated metabolites of carbamazepine and phenytoin.
Lu W; Uetrecht JP
Drug Metab Dispos; 2008 Aug; 36(8):1624-36. PubMed ID: 18463199
[TBL] [Abstract][Full Text] [Related]
39. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
Lynch T; Price A
Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
[TBL] [Abstract][Full Text] [Related]
40. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
